Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on June 30, 2009
JNCI Journal of the National Cancer Institute 2009 101(16):1158; doi:10.1093/jnci/djp202
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
101/16/1158    most recent
djp202v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Pointreau, Y.
Right arrow Articles by Calais, G.
PubMed
Right arrow Articles by Pointreau, Y.
Right arrow Articles by Calais, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press.

CORRESPONDENCE

Response: Re: Randomized Trial of Induction Chemotherapy With Cisplatin and 5-Fluorouracil With or Without Docetaxel for Larynx Preservation

Yoann Pointreau, Gilles Calais

Affiliation of authors: Radiotherapy Unit, Centre Hospitalier Régional et Universitaire, Henry Kaplan Center, Clinique d'Oncologie et de Radiothérapie, Tours, France

Correspondence to: Yoann Pointreau, MD, Radiotherapy Unit, Centre Hospitalier Régional et Universitaire, Henry Kaplan Center, Clinique d'Oncologie et de Radiothérapie, 2 Blvd Tonnellé, 37044 Tours, France (e-mail: pointr_y@yahoo.fr).

The first 10% of the full text of this article appears below.

We thank Dr Haddad for raising important issues. The Groupe d’Oncologie Radiotherapie Tete Et Cou (GORTEC) 2000-01 trial was especially designed for organ preservation, and the primary endpoint . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?